Europe – Respiratory vaccination candidate tested in German hospitals

Novel tuberculosis vaccine tested in a large phase 3 trial against severe respiratory infection disease

Researchers are investigating whether the vaccine candidate VPM1002 – originally developed against tuberculosis by scientists at the Max Planck Institute for Infection Biology, Berlin – is also protective against COVID-19 infection.

A large-scale study has been carried out at several hospitals in Germany and included older people that are susceptible to severe disease. VPM1002 induces specific immunity against tuberculosis, but at the same time mobilises innate immunity, which is immediately effective against a variety of pathogens…